Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

05 April 2022: Original Paper

Okjoo Lee ^1ABCDEF , Jinsoo Rhu ^1ABCDE* , Gyu-Seong Choi ^1ABCDE , Jong Man Kim ^1CD , Kyunga Kim ^2CD , Jae-Won Joh ^1CD

DOI: 10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

Table 3 The risk factors of hepatocellular carcinoma recurrence analyzed by Cox proportional-hazards regression models.

Recipient characteristics	Univariable			Multivariable
Recipient characteristics	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Sex (Male)	1.968	0.959–4.039	0.065	1.317	0.634–2.739	0.460	1.321	0.635–2.747	0.457
Age (≥60 years)	0.732	0.455–1.175	0.196
MELD score (≥20 points)	0.798	0.372–1.716	0.564
ABO-incompatible LT	1.258	0.767–2.063	0.364
Regional treatment (≥3 times)	2.381	1.637–3.461		1.775	1.204–2.616	0.004	1.784	1.210–2.629	0.004
Tumor size (≥3 cm)	2.347	1.617–3.406		1.570	1.070–2.304	0.021	1.561	1.065–2.288	0.022
Tumor number (≥3)	1.877	1.285–2.742	0.001	1.267	0.861–1.864	0.231	1.272	0.863–1.873	0.224
AFP (≥100 ng/dL)	2.923	2.013–4.243		1.912	1.293–2.828	0.001	1.911	1.293–2.825	0.001
Poor pathologic finding (Edmonson criteria ≥3)	1.451	0.842–2.501	0.181
Microvascular invasion	5.373	3.394–8.505		3.408	2.085–5.572		3.379	2.067–5.523
Low GRWR (	1.975	1.000–3.903	0.050	1.373	0.689–2.736	0.367	1.379	0.692–2.748	0.361
Statin user	1.277	0.510–3.193	0.602	0.929	0.366–2.357	0.877
cDDD	1.231	0.813–1.863	0.326				1.107	0.706–1.736	0.658
^* Statin user and, cDDD were considered as time dependent covariates. MELD – model for end-stage liver disease; AFP – alpha-fetoprotein; GRWR – graft-recipient weight ratio; cDDD – cumulative defined daily dose.